Vanda Pharmaceuticals Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on March 1, 2018, reporting events that occurred on February 28, 2018. The filing details the Compensation Committee's decisions regarding executive compensation, including 2017 annual bonuses, 2018 base salaries, 2018 bonus targets, and new equity grants for named executive officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation figures.
Material Changes and Compensation Details
The Compensation Committee awarded 2017 annual bonuses and approved 2018 compensation packages following a peer group analysis by Willis Towers Watson. Additionally, stock options and restricted stock units (RSUs) were granted.
- 2017 Annual Bonuses:
- Dr. Mihael Polymeropoulos (CEO): $502,200
- James P. Kelly (CFO): $216,225
- Richard L. Gulino (General Counsel): $128,340
- Gian Piero Reverberi (CCO): 198,369 CHF
- Gunther Birznieks (SVP Business Development): $195,000
- 2018 Base Salaries and Target Bonuses:
- Dr. Mihael Polymeropoulos: $700,000 base; 80% target bonus
- James P. Kelly: $479,000 base; 50% target bonus
- Richard L. Gulino: $355,000 base; 40% target bonus
- Gian Piero Reverberi: 488,000 CHF base; 45% target bonus
- Gunther Birznieks: $375,000 base; 40% target bonus
- Equity Grants (Feb 28, 2018):
- Stock Options: Exercise price of $18.85 per share (closing price on grant date). Vesting occurs in equal monthly installments over four years.
- RSUs: Vest in four equal annual installments beginning February 28, 2019.
- Grant Sizes:
- Dr. Polymeropoulos: 140,000 options; 60,000 RSUs
- James P. Kelly: 80,000 options; 40,000 RSUs
- Richard L. Gulino: 70,000 options; 30,000 RSUs
- Gian Piero Reverberi: 70,000 options; 30,000 RSUs
- Gunther Birznieks: 70,000 options; 30,000 RSUs
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. The document is strictly limited to the disclosure of executive compensation arrangements.
Key Facts for Investor Verification
- Verify the total cash compensation cost for 2017 bonuses and 2018 salary increases against the company's cash position.
- Confirm the dilution impact of the 430,000 new stock options and 190,000 new RSUs granted to executives.
- Note that compensation for the Chief Commercial Officer is denominated in Swiss Francs (CHF), requiring currency conversion for total cost analysis.
- Review the vesting schedules to understand future cash or equity obligations over the next four years.